83例AML1/ETO阳性急性髓系白血病的分子生物学和临床特点分析

赵杰; 殷宇明; 杨君芳; 费新红; 赵艳丽; 王静波; 孙媛; 张弦; 单褔香; 李倩; 刘红星; 王卉; 王彤; 童春容; 吴彤; 陆道培

83例AML1/ETO阳性急性髓系白血病的分子生物学和临床特点分析

- 北京市道培医院(北京, 100049)

详细信息

通讯作者: 赵杰,E-mail:zhaojie329@126.com

中图分类号: R733.71

收稿日期: 2011-10-05

Clinical and molecular characteristics in 83 cases of acute leukemia with AML1/ETO

- Beijing Daopei Hospital, Beijing, 100049, China

More Information

Corresponding author: ZHAO Jie, E-mail: zhaojie329@126.com

Received Date: 05 October 2011

摘要

摘要: 目的:分析AML1/ETO阳性急性髓系白血病(AML)患者的分子生物学和临床特点,探讨治疗策略。方法:对83例AML1/ETO阳性的AML患者的形态学、免疫学、分子生物学、染色体特征以及治疗、生存情况进行分析总结。结果:83例AML1/ETO阳性的AML患者中,髓外浸润17例(20.4%),白细胞大于10×10⁹/L的47例(57.8%);45例患者表达CD56抗原(60.8%),29例表达CD19抗原(39.2%);有65例患者检测到t (8;21)异位,其中包括单独t (8;21)异位的28例(43.1%)、伴有附加染色体的37例(56.9%);83例患者均进行了诱导化疗,总缓解率为79.5%,66例缓解后的患者有17例在6个月内复发,复发率为25.9%;83例患者共存活42例,死亡41例,中位生存期为26(2~113)个月;有36例进行了异基因造血干细胞移植(HSCT),25例存活,3年OS率67.5%,5年OS是56.6%,另外47例接受化疗的患者3年OS率36.4%;预后因素分析显示,患者的年龄、CD56的表达对OS率的影响差异无统计学意义,而初诊时白细胞数目、髓外浸润、有无附加染色体以及治疗的情况(化疗和移植)对OS率的影响差异有统计学意义;采用异基因造血干细胞移植的患者的OS率明显高于接受化疗的患者 (P<0.01)。结论:AML1/ETO阳性AML患者易并发高危因素,异基因造血干细胞移植可明显改善AML1/ETO阳性AML患者的生存。
- AML1/ETO阳性AML /
- 疾病特征 /
- 治疗预后
Abstract: Objective:To analyze the clinical and molecular characteristics of acute leukemia with AML1/ETO and explore the reasonable therapeutic principles.Method:Characteristics in morphology, immunology, molecular biology, cytogenetics, treatment and overall survival in 83 cases of acute leukemia with AML1/ETO were studied and analyzed. Result:Within 83 cases of acute leukemia with AML1/ETO, 17 cases(20.4%) had extramedullary infiltration, 47 cases(57.8%) with WBC count greater than 10×10⁹/L, 45 cases(60.8%) with CD56 antigen positive, 29 cases(39.2%) with CD19 antigen positive. 65 patients had t(8;21) translocation which included 28 cases of t(8;21)translocation alone(43.1%), 37 cases(56.9%) with additional chromosome abnormality. All the 83 patients received induction chemotherapy and the overall CR rate was 79.5%, 17 patients relapsed within 6 months after CR in 66 patients who had achieved CR and the relapse rate was 25.9%. In 83 cases, 42 cases survived and 41 cases died, the median survival time was 26(range 2-113) months. 36 cases received allo-hematopoietic stem cell transplantation(HSCT), 25 cases survived and 3-year overall survival rate was 67.5%, 5-year overall survival rate was 56.6%. The 3-year overall survival rate was 36.4% in 47 patients who received chemotherapy. The analysis of prognosis factors showed that the patients’age and whether they express CD56 antigen or not had no statistical effect on overall survival, but the WBC count at the presentation, extramedullary infiltration, additional chromosome abnormality and treatment regimen (chemotherapy or transplantation) had statistical effects on overall survival. The overall survival in patients after HSCT was much higher than that in patients who received chemotherapy(P<0.01).Conclusion:Acute leukemia patients with AML1/ETO would be prone to accompanied with high-risk factors, and HSCT could obviously improve the survival conditions of these patients.
- acute leukemia with AML1/ETO /
- characteristics of disease /
- prognosis after treatment

HTML全文

参考文献(16)

[1]	ROWLEY J D. Identificaton of a translocation with quinacrine fluorescence in a patient witII acute leukemia[J]. Ann Geuet, 1973, 16:109-112.
[2]	ZHOU G B, KANG H, WANG L, et al. Oridonin,a diterpenoid extracted from medicinal herbs, targets AMLI-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(801) leukemia in vitro and in vivo[J]. Blood, 2007, 109:3441-3450.
[3]	PALLISGAARD N, HOKLAND P, RIISHOJ D C, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia[J]. Blood,1998, 92:574-588.
[4]	SLOVAK M L, KOPECKI K J, CASSILELH P A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Gmup/Eastern Cooperative Oneo\|ogy Group Study[J]. Blood, 2000, 96:4075-4083.
[5]	MROZEK K, HEINONEN K, BLCONLFIELD C D. Prognostic value of cytogenetic findings in adults witlI acute myeloid leukemia[J]. Int J Hematol, 2000, 72:261-271.
[6]	LEE K W, CHOI I S, ROH E Y, et al. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21):a single institution's experience[J]. Ann Hematol, 2004, 83:218-224.
[7]	石红霞, 江滨, 丘镜莹,等. 成人t (8; 21)急性髓系白血病M2型治疗方案及预后分析[J]. 中华血液学杂志, 2005, 26(8):481-484.
[8]	BILLSTROM R, JOHANSSON B, FIORETOS T, et al. Poor survival of in t (8;21) (q22; q22) 2 ass ociated acute myeloid leukaemia with leukocytosis[J]. Eur J Haemat ol, 1997, 59:472-478.
[9]	薛惠良, 陈静, 沈树红,等. AML1-ETO阳性的儿童急性髓系白血病疗效分析[J]. 中国小儿血液与肿瘤杂志, 2010, 15(2):62-64.
[10]	李红艺, 岳寒, 魏旭东,等. 含大剂量阿糖胞苷方案强化治疗t (8;21)和正常核型急性髓系白血病M2患者疗效比较[J]. 中华血液学杂志, 2008, 29(2):110-112.
[11]	殷宇明, 吴彤, 王静波,等. 异基因造血干细胞移植治疗AML1/ETO (+)急性髓系白血病的疗效[J]. 临床血液学杂志, 2010, 23(5):262-265.
[12]	LANCET J E, COJO I, GOFLIB J, et al. A pha-study of the famesyltransferase inhibitor tipifamib in poor-risk and elderly patients with previously untreated acute myelogenons leukemia[J]. Blood, 2007, 109:1387-1394.
[13]	苗雨青, 陈子兴, 何军,等. AML1/ETO9a异构体在M₂型急性髓系白血病中表达的研究[J]. 中华血液学杂志, 2007, 28(1):27-29.
[14]	曾慧敏, 郭晔, 竺晓凡,等. t(8; 21)急性髓系白血病发病机制的研究进展[J]. 中国实验血液学杂志, 2010, 18(6):1632- 1637.
[15]	SUSANNE S, TOBIAS M K, TORSTEN H, et al. KIT-D816mutationsin AML1-ETO-positiveAML areassociatedwithimpaired event-freeandoverallsurvival[J]. Blood, 2006, 107:1791-1799.
[16]	HANG D C, SHIH L Y, HUANG C F, et al. Different cooperating mutation patterns of receptor tyrosine kinase/Ras/JAK2 between de novo AMLl-ETO and CBF-MYHl 1 acute myloid leukemia[J]. Blood, 2007, 110: 3487a-3492a.